- SYSADOA, chondroprotektiva, DMARD2005 | First Faculty of Medicine
- Specific clinical features of late-onset rheumatoid arthritis2014 | First Faculty of Medicine
- Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access2017 | First Faculty of Medicine
- Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs.Publication without faculty affiliation
- Subcutaneous tocilizumab in the treatment of rheumatoid arthritis2018 | First Faculty of Medicine
- Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution2019 | First Faculty of Medicine
- Analysis of Reasons for Discontinuation of DMARDs n Patients with Rheumatoid Arthritis2001 | Faculty of Mathematics and Physics
- Analysis of reasons for discontinuation of DMARDs in patients with rheumatoid arthritis2001 | First Faculty of Medicine
- Rheumatic manifestations in HIV2019 | First Faculty of Medicine
- Can DMARDs therapy of rheumatoid arthritis be as effective as biological treatment? Case-controled studyPublication without faculty affiliation
- Analysis of the Reasons of DMARD Therapy Discontinuation in Patients with Rheumatoid Arthritis in Czech and Slovak Republics2002 | First Faculty of Medicine
- Unusual situations in rheumatoid arthritis treatment2019 | Faculty of Medicine in Hradec Králové
- ASAS‑EULAR recommendations for the treatment of axial spondylarthritis: an update2023 | First Faculty of Medicine
- Analysis of the resons for DMARD therapy discontinuation in patients with rheumatoid arthritis in the Czech and Slovak Republics2002 | Faculty of Physical Education and Sport
- The effect of treatment of rheumatic diseases on cardiovascular risk2018 | First Faculty of Medicine
- Leflunomide in the current treatment algorithm for rheumatoid arthritis.2009 | First Faculty of Medicine
- Current possibilities of juvenile idiopathic arthritis treatment2018 | First Faculty of Medicine
- Nimesulid for local aplication2010 | First Faculty of Medicine
- The Czech Rheumatological Society recommendations for monitoring the treatment safety in rheumatoid arthritis.2009 | First Faculty of Medicine
- Analysis of DMARDs combination therapy in patients with rheumatoid arthritis in the Czech and Slovak republics2001 | First Faculty of Medicine
- Therapy of rheumatoid arthritis with synthetic and biological disease modifying drugs.2009 | First Faculty of Medicine
- Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study2009 | First Faculty of Medicine
- Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial2013 | First Faculty of Medicine
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice2012 | First Faculty of Medicine
- Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs2012 | First Faculty of Medicine
- Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology2015 | First Faculty of Medicine
- Methotrexate and its role in rheumatology daily practice2019 | First Faculty of Medicine
- Factors effecting efficacy in anti-TNF therapy in clinical practice: Experiences from national registry ATTRA2014 | First Faculty of Medicine
- Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study2018 | First Faculty of Medicine
- The therapy of ocular manifestations of immune mediated inflammatory diseases2019 | First Faculty of Medicine